Indian clinical stage biopharmaceutical company, demerged from Sun Pharmaceutical Industries in 2007 and listed on the Indian exchanges, with its research centre at Tandalja in Vadodara, Gujarat. Develops innovative therapeutics in oncology and immunology, including antibody drug conjugates against MUC1 carrying MMAE and exatecan payloads, bispecific conjugates, T-cell engagers and DNA damage response programmes, alongside earlier work on novel drug delivery platforms, and licenses and partners its candidates for further development.
Aucun commentaire disponible.
Laissez votre note & commentaire